4SC AG - Company Profile

Powered by

All the data and insights you need on 4SC AG in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date 4SC AG Strategy Report

  • Understand 4SC AG position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

4SC AG: Overview

Select Item

4SC AG (4SC) is a clinical-stage biopharmaceutical company engaged in developing small molecule drugs for the treatment of cancer. The company’s product portfolio focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its small molecule product pipeline comprises of Resminostat for histone deacetylase (HDAC) inhibitor. 4SC’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. The company develops and commercializes its products through partnerships and collaborations with pharmaceutical and biotech companies mainly in the European and Asian markets. 4SC is headquartered in Planegg-Martinsried, Germany.

 Gain a 360-degree view of 4SC AG and make more informed decisions for your business Gain a 360-degree view of 4SC AG and make more informed decisions for your business Find out more
Headquarters Germany
Address Fraunhoferstr. 22, Planegg, Bayern, 82152
Website www.4sc.de
Telephone 49 89 7007630
No of Employees 15
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange VSC (FRA)
Revenue (2022) $328,800 -30.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 42.6% (2022 vs 2021)
Market Cap* $87.0M
Net Profit Margin (2022) XYZ 17.7% (2022 vs 2021)
* As of and is in US$
View 4SC AG financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

4SC AG premium industry data and analytics

40+

Pipeline Drugs

Identify which of 4SC AG’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Clinical Trials

Determine 4SC AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Catalyst Calendar

Proactively evaluate 4SC AG’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
Pipeline
Resminostat- histone deacetylase (HDAC) inhibitor
Domatinostat (4SC-202)- class I selective HDAC inhibitor
XYZ
XYZ
XYZ
Understand 4SC AG portfolio and identify potential areas for collaboration Understand 4SC AG portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters 4SC AG Galapagos NV SymBio Pharmaceuticals Ltd Taiho Pharmaceutical Co Ltd MediGene AG
Headquarters Germany Belgium Japan Japan Germany
City Planegg Malines (Mechelen) Minato-Ku Tokyo Planegg
State/Province Bayern - Tokyo Tokyo Bayern
No. of Employees 15 646 118 2,170 86
Entity Type Public Public Public Private Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Clemens Doppler, Ph.D. Chairman Executive Board 2014 -
Jason Loveridge, Ph.D. Chief Executive Officer Senior Management 2016 -
Kathleen Masch Wiest Chief Operating Officer Senior Management 2022 -
Susanne Danhauser-Riedl, M.D. Chief Medical Officer Senior Management 2015 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into 4SC AG key executives to enhance your sales strategy Gain insight into 4SC AG key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward